| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 594 | 2024 | 11727 | 16.050 |
Why?
|
| Acute Coronary Syndrome | 145 | 2023 | 2337 | 12.360 |
Why?
|
| Angina, Unstable | 108 | 2021 | 926 | 11.120 |
Why?
|
| Thrombolytic Therapy | 157 | 2021 | 2161 | 9.950 |
Why?
|
| Heart Failure | 241 | 2024 | 10900 | 8.610 |
Why?
|
| Platelet Aggregation Inhibitors | 131 | 2021 | 3068 | 7.180 |
Why?
|
| Cardiology | 41 | 2024 | 1668 | 7.000 |
Why?
|
| Simvastatin | 26 | 2021 | 360 | 6.440 |
Why?
|
| Pravastatin | 45 | 2016 | 395 | 5.610 |
Why?
|
| Coronary Disease | 171 | 2018 | 6077 | 5.560 |
Why?
|
| Anticholesteremic Agents | 47 | 2023 | 979 | 5.510 |
Why?
|
| Thiazoles | 46 | 2022 | 1483 | 5.370 |
Why?
|
| Pyridines | 77 | 2022 | 2825 | 5.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 70 | 2023 | 3255 | 4.970 |
Why?
|
| Fibrinolytic Agents | 105 | 2016 | 2158 | 4.910 |
Why?
|
| Cholesterol, LDL | 41 | 2022 | 2356 | 4.730 |
Why?
|
| Cardiomyopathy, Hypertrophic | 34 | 2024 | 1265 | 4.560 |
Why?
|
| Thiophenes | 39 | 2014 | 588 | 4.210 |
Why?
|
| Electrocardiography | 193 | 2020 | 6442 | 4.000 |
Why?
|
| Warfarin | 43 | 2024 | 1496 | 4.000 |
Why?
|
| Tetrazoles | 21 | 2024 | 835 | 3.840 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 53 | 2014 | 641 | 3.840 |
Why?
|
| Angioplasty, Balloon, Coronary | 84 | 2011 | 1873 | 3.820 |
Why?
|
| Anticoagulants | 81 | 2024 | 4599 | 3.720 |
Why?
|
| Atrial Fibrillation | 74 | 2024 | 5034 | 3.610 |
Why?
|
| Piperazines | 53 | 2014 | 2488 | 3.540 |
Why?
|
| Natriuretic Peptide, Brain | 50 | 2024 | 1573 | 3.490 |
Why?
|
| Heptanoic Acids | 26 | 2011 | 343 | 3.470 |
Why?
|
| Double-Blind Method | 190 | 2024 | 12026 | 3.430 |
Why?
|
| Enoxaparin | 30 | 2010 | 377 | 3.190 |
Why?
|
| Angiotensin Receptor Antagonists | 22 | 2024 | 924 | 3.150 |
Why?
|
| Tissue Plasminogen Activator | 68 | 2007 | 1261 | 3.150 |
Why?
|
| Cardiovascular System | 8 | 2024 | 832 | 3.000 |
Why?
|
| Ticlopidine | 43 | 2015 | 899 | 2.960 |
Why?
|
| Hemorrhage | 89 | 2024 | 3461 | 2.890 |
Why?
|
| Biphenyl Compounds | 23 | 2024 | 913 | 2.800 |
Why?
|
| Stroke Volume | 86 | 2024 | 5007 | 2.760 |
Why?
|
| Coronary Angiography | 103 | 2022 | 4577 | 2.650 |
Why?
|
| Stroke | 91 | 2024 | 9981 | 2.600 |
Why?
|
| Tyrosine | 26 | 2011 | 1461 | 2.580 |
Why?
|
| Pyrroles | 26 | 2011 | 1146 | 2.530 |
Why?
|
| C-Reactive Protein | 41 | 2024 | 3778 | 2.480 |
Why?
|
| Enalapril | 11 | 2024 | 327 | 2.420 |
Why?
|
| Humans | 1145 | 2024 | 744343 | 2.380 |
Why?
|
| Myocardial Ischemia | 44 | 2021 | 2148 | 2.380 |
Why?
|
| Adamantane | 17 | 2021 | 173 | 2.290 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 40 | 2024 | 1518 | 2.260 |
Why?
|
| Neprilysin | 11 | 2024 | 439 | 2.240 |
Why?
|
| Coronary Circulation | 88 | 2012 | 1572 | 2.210 |
Why?
|
| Heart | 130 | 2023 | 4467 | 2.170 |
Why?
|
| Troponin I | 24 | 2018 | 619 | 2.160 |
Why?
|
| Dipeptides | 17 | 2021 | 409 | 2.140 |
Why?
|
| Treatment Outcome | 286 | 2024 | 63114 | 2.070 |
Why?
|
| Secondary Prevention | 48 | 2024 | 1530 | 2.030 |
Why?
|
| Cholesterol | 23 | 2022 | 2917 | 2.000 |
Why?
|
| Acetanilides | 19 | 2014 | 168 | 2.000 |
Why?
|
| Coronary Artery Disease | 35 | 2022 | 6487 | 1.970 |
Why?
|
| Cardiovascular Diseases | 88 | 2024 | 15165 | 1.930 |
Why?
|
| Aged | 450 | 2024 | 163280 | 1.850 |
Why?
|
| Randomized Controlled Trials as Topic | 107 | 2024 | 9959 | 1.850 |
Why?
|
| Ventricular Function, Left | 36 | 2024 | 3670 | 1.840 |
Why?
|
| Drug Combinations | 28 | 2024 | 1959 | 1.800 |
Why?
|
| Heparin | 41 | 2010 | 1637 | 1.790 |
Why?
|
| Middle Aged | 539 | 2023 | 213383 | 1.790 |
Why?
|
| Diabetes Mellitus, Type 2 | 34 | 2023 | 11725 | 1.790 |
Why?
|
| Myocardial Reperfusion | 24 | 2012 | 351 | 1.750 |
Why?
|
| Peptide Fragments | 33 | 2024 | 5097 | 1.750 |
Why?
|
| History, 20th Century | 39 | 2018 | 2740 | 1.750 |
Why?
|
| Ramipril | 7 | 2024 | 95 | 1.740 |
Why?
|
| Male | 646 | 2024 | 350118 | 1.740 |
Why?
|
| Lactones | 17 | 2016 | 329 | 1.680 |
Why?
|
| Drug Therapy, Combination | 76 | 2023 | 6489 | 1.680 |
Why?
|
| Female | 641 | 2024 | 380194 | 1.670 |
Why?
|
| Thrombosis | 25 | 2023 | 2968 | 1.650 |
Why?
|
| Coronary Artery Bypass | 42 | 2021 | 2289 | 1.640 |
Why?
|
| Angina Pectoris | 49 | 2012 | 977 | 1.630 |
Why?
|
| Cardiotonic Agents | 23 | 2021 | 535 | 1.600 |
Why?
|
| Myocardium | 123 | 2021 | 4776 | 1.550 |
Why?
|
| Risk Assessment | 104 | 2023 | 23338 | 1.480 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 21 | 2020 | 361 | 1.470 |
Why?
|
| Heart Septum | 13 | 2022 | 313 | 1.470 |
Why?
|
| Dose-Response Relationship, Drug | 75 | 2021 | 10943 | 1.420 |
Why?
|
| Myocardial Revascularization | 29 | 2021 | 841 | 1.380 |
Why?
|
| Biomedical Research | 15 | 2016 | 3309 | 1.380 |
Why?
|
| Ventricular Dysfunction, Left | 18 | 2024 | 2073 | 1.360 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 96 | 1.360 |
Why?
|
| Embolism | 16 | 2023 | 408 | 1.350 |
Why?
|
| Adenosine | 16 | 2020 | 825 | 1.340 |
Why?
|
| Aspirin | 47 | 2021 | 3282 | 1.300 |
Why?
|
| Hypolipidemic Agents | 10 | 2019 | 604 | 1.280 |
Why?
|
| Dyslipidemias | 4 | 2022 | 849 | 1.210 |
Why?
|
| Coronary Thrombosis | 15 | 2015 | 495 | 1.200 |
Why?
|
| Platelet Function Tests | 5 | 2008 | 270 | 1.190 |
Why?
|
| Recurrence | 81 | 2019 | 8340 | 1.190 |
Why?
|
| Plasminogen Activators | 14 | 2004 | 209 | 1.180 |
Why?
|
| Oxygen Consumption | 67 | 2018 | 1869 | 1.180 |
Why?
|
| Immunoglobulin Fab Fragments | 19 | 2008 | 482 | 1.170 |
Why?
|
| Azetidines | 6 | 2015 | 142 | 1.170 |
Why?
|
| Digoxin | 6 | 2017 | 250 | 1.160 |
Why?
|
| Troponin T | 17 | 2022 | 754 | 1.150 |
Why?
|
| Risk Factors | 170 | 2024 | 72290 | 1.150 |
Why?
|
| Heart Diseases | 34 | 2018 | 2788 | 1.140 |
Why?
|
| Atrial Natriuretic Factor | 10 | 2014 | 393 | 1.130 |
Why?
|
| Prognosis | 111 | 2024 | 29063 | 1.130 |
Why?
|
| Kidney | 19 | 2023 | 7186 | 1.120 |
Why?
|
| Hospitalization | 47 | 2021 | 10262 | 1.110 |
Why?
|
| Acute Disease | 72 | 2021 | 7149 | 1.100 |
Why?
|
| Cardiovascular Agents | 15 | 2014 | 850 | 1.100 |
Why?
|
| Purinergic P2 Receptor Antagonists | 7 | 2011 | 71 | 1.090 |
Why?
|
| Cardiomyopathies | 10 | 2023 | 1912 | 1.080 |
Why?
|
| Vasodilator Agents | 18 | 2016 | 977 | 1.080 |
Why?
|
| Blood Platelets | 12 | 2016 | 2508 | 1.060 |
Why?
|
| Captopril | 19 | 2004 | 272 | 1.060 |
Why?
|
| History, 21st Century | 18 | 2016 | 1534 | 1.050 |
Why?
|
| Troponin | 16 | 2020 | 524 | 1.050 |
Why?
|
| Follow-Up Studies | 123 | 2021 | 39050 | 1.040 |
Why?
|
| Diuretics | 11 | 2014 | 592 | 1.030 |
Why?
|
| Drug-Eluting Stents | 8 | 2021 | 753 | 1.020 |
Why?
|
| Coronary Vessels | 63 | 2016 | 3107 | 1.010 |
Why?
|
| Hemodynamics | 113 | 2019 | 4199 | 1.000 |
Why?
|
| Hypoglycemic Agents | 16 | 2022 | 2872 | 1.000 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 13 | 2021 | 293 | 0.980 |
Why?
|
| Atherosclerosis | 17 | 2024 | 3445 | 0.970 |
Why?
|
| Time Factors | 157 | 2021 | 40075 | 0.970 |
Why?
|
| Aortic Valve Stenosis | 26 | 2024 | 1965 | 0.970 |
Why?
|
| Clinical Trials as Topic | 52 | 2020 | 7913 | 0.960 |
Why?
|
| Dogs | 153 | 2007 | 3912 | 0.930 |
Why?
|
| Exercise Tolerance | 13 | 2018 | 770 | 0.910 |
Why?
|
| Myocardial Contraction | 45 | 2009 | 1585 | 0.900 |
Why?
|
| Factor XI | 1 | 2023 | 26 | 0.900 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 3505 | 0.900 |
Why?
|
| Angiotensinogen | 1 | 2023 | 163 | 0.900 |
Why?
|
| Myoglobin | 8 | 2006 | 160 | 0.890 |
Why?
|
| Antithrombins | 5 | 2007 | 304 | 0.880 |
Why?
|
| Syndrome | 39 | 2008 | 3251 | 0.870 |
Why?
|
| Drug Resistance | 5 | 2008 | 1609 | 0.870 |
Why?
|
| Creatine Kinase | 38 | 2004 | 694 | 0.860 |
Why?
|
| Cardiomegaly | 28 | 2013 | 620 | 0.840 |
Why?
|
| Glucosides | 3 | 2024 | 451 | 0.840 |
Why?
|
| Physiology | 14 | 2016 | 115 | 0.830 |
Why?
|
| Heart Failure, Diastolic | 3 | 2018 | 69 | 0.810 |
Why?
|
| Survival Rate | 52 | 2021 | 12788 | 0.810 |
Why?
|
| Predictive Value of Tests | 55 | 2021 | 15076 | 0.810 |
Why?
|
| Factor Xa | 4 | 2018 | 162 | 0.800 |
Why?
|
| Morpholines | 7 | 2013 | 571 | 0.800 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2017 | 269 | 0.800 |
Why?
|
| Drug Administration Schedule | 36 | 2019 | 4933 | 0.790 |
Why?
|
| Proportional Hazards Models | 51 | 2021 | 12354 | 0.760 |
Why?
|
| Research Design | 29 | 2020 | 5987 | 0.760 |
Why?
|
| Death, Sudden, Cardiac | 15 | 2024 | 1541 | 0.760 |
Why?
|
| Administration, Oral | 29 | 2024 | 3913 | 0.750 |
Why?
|
| Adrenergic beta-Antagonists | 31 | 2016 | 1240 | 0.740 |
Why?
|
| Renin-Angiotensin System | 9 | 2020 | 759 | 0.740 |
Why?
|
| Survival Analysis | 46 | 2019 | 10252 | 0.730 |
Why?
|
| Diabetes Mellitus | 24 | 2023 | 5751 | 0.720 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2022 | 339 | 0.720 |
Why?
|
| Iron Compounds | 2 | 2017 | 20 | 0.710 |
Why?
|
| Vascular Patency | 21 | 2016 | 886 | 0.710 |
Why?
|
| Natriuretic Peptides | 5 | 2015 | 150 | 0.710 |
Why?
|
| Hypertension | 31 | 2023 | 8480 | 0.700 |
Why?
|
| Creatinine | 14 | 2018 | 1919 | 0.700 |
Why?
|
| Receptor, PAR-1 | 8 | 2016 | 113 | 0.700 |
Why?
|
| Isosorbide Dinitrate | 3 | 2016 | 34 | 0.700 |
Why?
|
| Neopterin | 2 | 2011 | 56 | 0.700 |
Why?
|
| Diabetic Nephropathies | 5 | 2019 | 984 | 0.690 |
Why?
|
| Hirudin Therapy | 8 | 2002 | 43 | 0.680 |
Why?
|
| Antihypertensive Agents | 5 | 2023 | 2046 | 0.680 |
Why?
|
| Kidney Diseases | 10 | 2022 | 2149 | 0.680 |
Why?
|
| Risk | 35 | 2021 | 9687 | 0.680 |
Why?
|
| Pyrrolidines | 9 | 2007 | 342 | 0.680 |
Why?
|
| Drug Industry | 3 | 2016 | 746 | 0.670 |
Why?
|
| Recombinant Proteins | 24 | 2013 | 6622 | 0.670 |
Why?
|
| Blood Pressure | 136 | 2023 | 8554 | 0.660 |
Why?
|
| Kaplan-Meier Estimate | 37 | 2017 | 6538 | 0.650 |
Why?
|
| Benzhydryl Compounds | 4 | 2024 | 845 | 0.640 |
Why?
|
| Intracranial Hemorrhages | 16 | 2021 | 855 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 16 | 2018 | 7279 | 0.640 |
Why?
|
| Platelet Aggregation | 9 | 2016 | 798 | 0.630 |
Why?
|
| Spironolactone | 3 | 2017 | 382 | 0.630 |
Why?
|
| Albuminuria | 3 | 2018 | 682 | 0.630 |
Why?
|
| Oximes | 8 | 2018 | 311 | 0.630 |
Why?
|
| Streptokinase | 16 | 2007 | 188 | 0.620 |
Why?
|
| Cardiac Output | 64 | 1986 | 854 | 0.620 |
Why?
|
| Ischemic Preconditioning, Myocardial | 3 | 2011 | 67 | 0.600 |
Why?
|
| Angiotensins | 8 | 2024 | 151 | 0.590 |
Why?
|
| United States | 76 | 2023 | 69872 | 0.580 |
Why?
|
| Glomerular Filtration Rate | 17 | 2023 | 2170 | 0.580 |
Why?
|
| Prospective Studies | 71 | 2024 | 53288 | 0.580 |
Why?
|
| Diabetic Angiopathies | 7 | 2015 | 818 | 0.570 |
Why?
|
| Ventricular Outflow Obstruction | 6 | 2020 | 272 | 0.560 |
Why?
|
| Protein Precursors | 7 | 2014 | 1154 | 0.550 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2019 | 451 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2023 | 2208 | 0.550 |
Why?
|
| Peptides | 17 | 2019 | 4409 | 0.540 |
Why?
|
| Multivariate Analysis | 39 | 2019 | 12245 | 0.540 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 602 | 0.540 |
Why?
|
| Receptors, Angiotensin | 5 | 2024 | 142 | 0.530 |
Why?
|
| Cholesterol, HDL | 10 | 2022 | 1814 | 0.530 |
Why?
|
| Hirudins | 5 | 2006 | 183 | 0.530 |
Why?
|
| Stents | 16 | 2021 | 3280 | 0.530 |
Why?
|
| Heart Conduction System | 13 | 2004 | 1047 | 0.530 |
Why?
|
| Heparin, Low-Molecular-Weight | 6 | 2005 | 339 | 0.530 |
Why?
|
| Heart Ventricles | 79 | 2024 | 3821 | 0.530 |
Why?
|
| Myocardial Reperfusion Injury | 6 | 2011 | 476 | 0.520 |
Why?
|
| Coronary Care Units | 7 | 2014 | 214 | 0.520 |
Why?
|
| Rejuvenation | 1 | 2016 | 91 | 0.520 |
Why?
|
| Cardiac Output, Low | 5 | 2018 | 195 | 0.520 |
Why?
|
| Circadian Rhythm | 6 | 2013 | 2624 | 0.520 |
Why?
|
| Platelet Activation | 5 | 2010 | 673 | 0.510 |
Why?
|
| Arrhythmias, Cardiac | 23 | 2011 | 2268 | 0.510 |
Why?
|
| Apolipoproteins B | 3 | 2022 | 374 | 0.510 |
Why?
|
| Severity of Illness Index | 33 | 2019 | 15540 | 0.500 |
Why?
|
| Renal Insufficiency | 8 | 2021 | 804 | 0.500 |
Why?
|
| Incidence | 40 | 2021 | 20947 | 0.500 |
Why?
|
| Enzyme Inhibitors | 15 | 2014 | 3798 | 0.500 |
Why?
|
| Cause of Death | 21 | 2021 | 3584 | 0.500 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 307 | 0.500 |
Why?
|
| Chemokine CCL2 | 3 | 2007 | 617 | 0.500 |
Why?
|
| Heart Rate | 105 | 2016 | 4091 | 0.500 |
Why?
|
| Peripheral Arterial Disease | 9 | 2022 | 1188 | 0.500 |
Why?
|
| Awards and Prizes | 2 | 2014 | 375 | 0.490 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2017 | 1519 | 0.490 |
Why?
|
| Hyaluronoglucosaminidase | 27 | 1988 | 133 | 0.490 |
Why?
|
| Fluoroquinolones | 7 | 2007 | 310 | 0.490 |
Why?
|
| Oxazolidinones | 3 | 2022 | 96 | 0.490 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2022 | 980 | 0.480 |
Why?
|
| Foundations | 1 | 2014 | 94 | 0.480 |
Why?
|
| HIV | 2 | 2019 | 1604 | 0.470 |
Why?
|
| Indoles | 12 | 2019 | 1839 | 0.470 |
Why?
|
| Interprofessional Relations | 3 | 2016 | 1011 | 0.470 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 5 | 2017 | 101 | 0.470 |
Why?
|
| Echocardiography | 23 | 2023 | 5102 | 0.460 |
Why?
|
| Stem Cell Transplantation | 3 | 2018 | 1620 | 0.460 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 64 | 0.450 |
Why?
|
| Oxygen | 17 | 2016 | 4189 | 0.450 |
Why?
|
| Hematinics | 1 | 2016 | 281 | 0.450 |
Why?
|
| Hypotension | 10 | 2023 | 884 | 0.450 |
Why?
|
| Exercise Test | 28 | 2018 | 2074 | 0.440 |
Why?
|
| Polymorphism, Genetic | 8 | 2009 | 4328 | 0.440 |
Why?
|
| Myocardial Stunning | 4 | 2001 | 68 | 0.430 |
Why?
|
| Ventricular Function | 21 | 2017 | 416 | 0.430 |
Why?
|
| Blood Glucose | 12 | 2020 | 6256 | 0.430 |
Why?
|
| Ventricular Septum | 2 | 2012 | 73 | 0.430 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2017 | 851 | 0.420 |
Why?
|
| Comorbidity | 19 | 2019 | 10388 | 0.420 |
Why?
|
| Infusions, Intravenous | 21 | 2014 | 2274 | 0.420 |
Why?
|
| Multicenter Studies as Topic | 20 | 2020 | 1677 | 0.410 |
Why?
|
| Heart Atria | 13 | 2021 | 1357 | 0.410 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2016 | 365 | 0.410 |
Why?
|
| Physical Examination | 1 | 2018 | 1237 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 19 | 2008 | 9274 | 0.410 |
Why?
|
| Ethanol | 2 | 2012 | 1342 | 0.410 |
Why?
|
| Patient Selection | 13 | 2020 | 4215 | 0.410 |
Why?
|
| Societies, Medical | 8 | 2021 | 3743 | 0.410 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2023 | 85 | 0.410 |
Why?
|
| Hypoglycemia | 4 | 2016 | 861 | 0.410 |
Why?
|
| International Cooperation | 4 | 2014 | 1420 | 0.410 |
Why?
|
| Disease Progression | 14 | 2023 | 13284 | 0.400 |
Why?
|
| Ischemic Postconditioning | 1 | 2011 | 25 | 0.400 |
Why?
|
| Creatine Kinase, MB Form | 9 | 2018 | 214 | 0.400 |
Why?
|
| Hypercholesterolemia | 5 | 2016 | 1151 | 0.400 |
Why?
|
| Diabetes Complications | 10 | 2009 | 1359 | 0.400 |
Why?
|
| Patient Care Planning | 1 | 2017 | 921 | 0.400 |
Why?
|
| Antifibrinolytic Agents | 2 | 2007 | 254 | 0.400 |
Why?
|
| Pyridones | 12 | 2011 | 712 | 0.390 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2011 | 58 | 0.390 |
Why?
|
| Vascular Resistance | 40 | 2014 | 936 | 0.390 |
Why?
|
| Thromboembolism | 5 | 2021 | 986 | 0.390 |
Why?
|
| Hemoglobins | 2 | 2009 | 1534 | 0.380 |
Why?
|
| Blood Flow Velocity | 40 | 2005 | 1423 | 0.380 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2022 | 789 | 0.380 |
Why?
|
| Odds Ratio | 25 | 2017 | 9849 | 0.380 |
Why?
|
| Benzaldehydes | 6 | 2018 | 58 | 0.380 |
Why?
|
| Blood Coagulation | 8 | 2021 | 1127 | 0.380 |
Why?
|
| Physical Exertion | 33 | 1992 | 695 | 0.380 |
Why?
|
| Animals | 220 | 2020 | 168757 | 0.380 |
Why?
|
| Fumarates | 2 | 2013 | 132 | 0.380 |
Why?
|
| Verapamil | 10 | 1987 | 244 | 0.370 |
Why?
|
| Vascular Diseases | 3 | 2018 | 1161 | 0.370 |
Why?
|
| Defibrillators, Implantable | 4 | 2019 | 1440 | 0.370 |
Why?
|
| Propanolamines | 4 | 2001 | 167 | 0.370 |
Why?
|
| Triglycerides | 9 | 2015 | 2454 | 0.370 |
Why?
|
| Hyperuricemia | 1 | 2013 | 211 | 0.370 |
Why?
|
| Alanine | 9 | 2007 | 572 | 0.370 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2024 | 859 | 0.370 |
Why?
|
| Regional Blood Flow | 32 | 2008 | 1525 | 0.370 |
Why?
|
| Hyperkalemia | 3 | 2023 | 218 | 0.360 |
Why?
|
| Forecasting | 12 | 2017 | 2951 | 0.360 |
Why?
|
| Longevity | 2 | 2017 | 1070 | 0.360 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 1504 | 0.360 |
Why?
|
| Point-of-Care Systems | 5 | 2001 | 1177 | 0.360 |
Why?
|
| Age Factors | 32 | 2019 | 18370 | 0.350 |
Why?
|
| Heart Transplantation | 2 | 2022 | 3110 | 0.350 |
Why?
|
| Norepinephrine | 36 | 1986 | 909 | 0.350 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 78 | 0.350 |
Why?
|
| Necrosis | 26 | 2013 | 1643 | 0.350 |
Why?
|
| Lipids | 7 | 2019 | 3305 | 0.350 |
Why?
|
| Nifedipine | 9 | 1991 | 226 | 0.350 |
Why?
|
| Ablation Techniques | 1 | 2012 | 249 | 0.350 |
Why?
|
| Valine | 2 | 2013 | 413 | 0.350 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2009 | 66 | 0.350 |
Why?
|
| Myocarditis | 5 | 2013 | 771 | 0.350 |
Why?
|
| Air Pollution | 1 | 2023 | 2286 | 0.350 |
Why?
|
| Polysaccharides | 1 | 2016 | 1053 | 0.340 |
Why?
|
| Drug Approval | 5 | 2019 | 742 | 0.340 |
Why?
|
| Quality of Life | 12 | 2020 | 12804 | 0.340 |
Why?
|
| Air Pollutants | 1 | 2023 | 2817 | 0.340 |
Why?
|
| Sympathetic Nervous System | 21 | 2020 | 514 | 0.330 |
Why?
|
| Isoenzymes | 16 | 2004 | 1726 | 0.330 |
Why?
|
| Cholestyramine Resin | 1 | 2008 | 24 | 0.330 |
Why?
|
| Calcium Channel Blockers | 11 | 1998 | 690 | 0.330 |
Why?
|
| Propranolol | 37 | 1988 | 502 | 0.330 |
Why?
|
| Furosemide | 4 | 2014 | 167 | 0.330 |
Why?
|
| Europe | 13 | 2023 | 3339 | 0.330 |
Why?
|
| United States Food and Drug Administration | 2 | 2015 | 1584 | 0.320 |
Why?
|
| Injections, Intravenous | 20 | 2014 | 1420 | 0.320 |
Why?
|
| Algorithms | 10 | 2020 | 13881 | 0.320 |
Why?
|
| Isoproterenol | 29 | 1980 | 399 | 0.320 |
Why?
|
| Amides | 2 | 2013 | 459 | 0.320 |
Why?
|
| Physicians | 4 | 2016 | 4567 | 0.320 |
Why?
|
| Lovastatin | 1 | 2008 | 120 | 0.320 |
Why?
|
| Aged, 80 and over | 35 | 2023 | 57776 | 0.320 |
Why?
|
| Anti-Retroviral Agents | 1 | 2018 | 1715 | 0.320 |
Why?
|
| Neurotransmitter Agents | 4 | 2008 | 647 | 0.310 |
Why?
|
| Thoracic Surgery | 13 | 2012 | 719 | 0.310 |
Why?
|
| Receptors, Thrombin | 4 | 2015 | 131 | 0.310 |
Why?
|
| Thrombin | 4 | 2013 | 598 | 0.310 |
Why?
|
| Diagnostic Imaging | 3 | 2013 | 3507 | 0.310 |
Why?
|
| Ultrasonography | 6 | 2018 | 5985 | 0.300 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1671 | 0.300 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 281 | 0.300 |
Why?
|
| Adult | 143 | 2023 | 214055 | 0.300 |
Why?
|
| Sex Factors | 22 | 2021 | 10397 | 0.300 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2016 | 135 | 0.300 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 879 | 0.290 |
Why?
|
| Career Choice | 2 | 2015 | 744 | 0.290 |
Why?
|
| Hyperemia | 2 | 2008 | 225 | 0.290 |
Why?
|
| Carotid Sinus | 14 | 1976 | 45 | 0.290 |
Why?
|
| Pulmonary Edema | 3 | 2024 | 414 | 0.290 |
Why?
|
| Endpoint Determination | 8 | 2017 | 601 | 0.290 |
Why?
|
| Mortality | 6 | 2021 | 2864 | 0.280 |
Why?
|
| Chlamydophila Infections | 2 | 2005 | 23 | 0.280 |
Why?
|
| Sulfones | 3 | 2013 | 437 | 0.280 |
Why?
|
| Incretins | 2 | 2018 | 88 | 0.270 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2011 | 257 | 0.270 |
Why?
|
| Benzylamines | 2 | 2023 | 223 | 0.270 |
Why?
|
| Cerebrovascular Disorders | 7 | 2018 | 1504 | 0.270 |
Why?
|
| Atrial Function, Left | 2 | 2019 | 173 | 0.270 |
Why?
|
| Hyperglycemia | 5 | 2013 | 1373 | 0.270 |
Why?
|
| Postoperative Care | 4 | 2008 | 1486 | 0.260 |
Why?
|
| Phospholipases A | 1 | 2006 | 216 | 0.260 |
Why?
|
| Cineangiography | 11 | 1999 | 124 | 0.260 |
Why?
|
| Cardiac Surgical Procedures | 19 | 2018 | 3537 | 0.260 |
Why?
|
| Natriuresis | 3 | 2002 | 124 | 0.260 |
Why?
|
| Leukocyte Count | 5 | 2019 | 1588 | 0.260 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 391 | 0.260 |
Why?
|
| Prazosin | 7 | 1981 | 96 | 0.260 |
Why?
|
| Growth Differentiation Factor 15 | 4 | 2023 | 176 | 0.260 |
Why?
|
| Reflex | 10 | 1984 | 365 | 0.260 |
Why?
|
| Ouabain | 15 | 1985 | 264 | 0.260 |
Why?
|
| Shock, Cardiogenic | 11 | 2010 | 688 | 0.260 |
Why?
|
| Heart Valve Diseases | 17 | 2017 | 1073 | 0.250 |
Why?
|
| Analysis of Variance | 12 | 2018 | 6365 | 0.250 |
Why?
|
| Research Personnel | 2 | 2008 | 573 | 0.250 |
Why?
|
| Renin | 7 | 2014 | 642 | 0.250 |
Why?
|
| Research | 15 | 2018 | 1999 | 0.250 |
Why?
|
| von Willebrand Factor | 2 | 2007 | 669 | 0.250 |
Why?
|
| Insulin | 16 | 2022 | 6580 | 0.250 |
Why?
|
| Nitroglycerin | 18 | 1998 | 325 | 0.240 |
Why?
|
| Potassium | 10 | 2022 | 1336 | 0.240 |
Why?
|
| HIV Infections | 3 | 2021 | 16718 | 0.240 |
Why?
|
| Cohort Studies | 31 | 2024 | 40561 | 0.240 |
Why?
|
| Pacemaker, Artificial | 12 | 2019 | 816 | 0.240 |
Why?
|
| Digitalis Glycosides | 12 | 2016 | 47 | 0.240 |
Why?
|
| Clinical Enzyme Tests | 7 | 2011 | 115 | 0.240 |
Why?
|
| Pericardium | 9 | 2021 | 667 | 0.240 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2021 | 68 | 0.240 |
Why?
|
| Health Status Indicators | 1 | 2009 | 969 | 0.230 |
Why?
|
| Lipoproteins, LDL | 5 | 2006 | 640 | 0.230 |
Why?
|
| Aortic Valve | 8 | 2023 | 1922 | 0.230 |
Why?
|
| Combined Modality Therapy | 14 | 2009 | 8642 | 0.230 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 789 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 15 | 1999 | 793 | 0.230 |
Why?
|
| Cystatin C | 4 | 2018 | 250 | 0.230 |
Why?
|
| Chlamydophila pneumoniae | 2 | 2005 | 55 | 0.230 |
Why?
|
| Congresses as Topic | 1 | 2008 | 764 | 0.220 |
Why?
|
| Angiotensin II | 2 | 2023 | 881 | 0.220 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2016 | 340 | 0.220 |
Why?
|
| Echocardiography, Doppler | 4 | 2017 | 935 | 0.220 |
Why?
|
| Heart Valve Prosthesis | 13 | 2001 | 1488 | 0.220 |
Why?
|
| Serum Amyloid A Protein | 2 | 2000 | 121 | 0.220 |
Why?
|
| Anti-Infective Agents | 4 | 2007 | 972 | 0.220 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 1125 | 0.220 |
Why?
|
| Uracil | 1 | 2023 | 165 | 0.210 |
Why?
|
| Death | 5 | 2020 | 678 | 0.210 |
Why?
|
| Thrombocytopenia | 3 | 2006 | 1179 | 0.210 |
Why?
|
| Inflammation | 11 | 2020 | 10638 | 0.210 |
Why?
|
| Canada | 7 | 2019 | 2065 | 0.210 |
Why?
|
| Chi-Square Distribution | 12 | 2012 | 3508 | 0.210 |
Why?
|
| Austria | 3 | 2012 | 203 | 0.210 |
Why?
|
| Piperidines | 3 | 1999 | 1602 | 0.210 |
Why?
|
| Calcium | 19 | 2014 | 5756 | 0.210 |
Why?
|
| Muscle Contraction | 23 | 1982 | 1240 | 0.210 |
Why?
|
| History, 19th Century | 3 | 2012 | 720 | 0.210 |
Why?
|
| Liver Diseases | 3 | 2019 | 1253 | 0.210 |
Why?
|
| Ischemia | 9 | 2016 | 1907 | 0.200 |
Why?
|
| Drug Monitoring | 3 | 2018 | 956 | 0.200 |
Why?
|
| Life Tables | 4 | 2006 | 370 | 0.200 |
Why?
|
| Galectin 3 | 2 | 2015 | 227 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 12 | 2020 | 5391 | 0.200 |
Why?
|
| Academic Medical Centers | 4 | 2006 | 2759 | 0.200 |
Why?
|
| History, 18th Century | 2 | 2012 | 214 | 0.200 |
Why?
|
| Electric Stimulation | 25 | 1977 | 1767 | 0.200 |
Why?
|
| Guideline Adherence | 5 | 2020 | 2266 | 0.200 |
Why?
|
| Patient Discharge | 6 | 2020 | 3313 | 0.200 |
Why?
|
| Proline | 4 | 1985 | 458 | 0.200 |
Why?
|
| Tachycardia | 12 | 2007 | 619 | 0.200 |
Why?
|
| Registries | 13 | 2017 | 8089 | 0.190 |
Why?
|
| Metabolic Clearance Rate | 4 | 2016 | 380 | 0.190 |
Why?
|
| Safety | 6 | 2009 | 1186 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2018 | 426 | 0.190 |
Why?
|
| Ventricular Remodeling | 5 | 2013 | 1224 | 0.190 |
Why?
|
| Primary Prevention | 3 | 2023 | 1167 | 0.190 |
Why?
|
| Schools, Medical | 2 | 2006 | 880 | 0.190 |
Why?
|
| Apolipoproteins C | 1 | 2000 | 59 | 0.190 |
Why?
|
| Quality of Health Care | 3 | 2011 | 4371 | 0.190 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 1956 | 0.190 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2585 | 0.190 |
Why?
|
| Evidence-Based Medicine | 4 | 2019 | 3610 | 0.190 |
Why?
|
| HIV Long-Term Survivors | 1 | 2021 | 126 | 0.190 |
Why?
|
| Cholesterol, VLDL | 1 | 2000 | 65 | 0.190 |
Why?
|
| Syncope | 1 | 2024 | 429 | 0.190 |
Why?
|
| Angioplasty | 3 | 2012 | 364 | 0.190 |
Why?
|
| Dyspnea | 5 | 2016 | 1303 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2012 | 780 | 0.190 |
Why?
|
| Electrocardiography, Ambulatory | 5 | 2011 | 585 | 0.190 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1194 | 0.190 |
Why?
|
| Myocytes, Cardiac | 3 | 2014 | 1637 | 0.190 |
Why?
|
| Methylamines | 1 | 2021 | 123 | 0.190 |
Why?
|
| Apolipoproteins | 2 | 2000 | 317 | 0.190 |
Why?
|
| Statistics as Topic | 11 | 2013 | 2373 | 0.190 |
Why?
|
| Partial Thromboplastin Time | 3 | 2004 | 206 | 0.190 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 2657 | 0.180 |
Why?
|
| Cross-Over Studies | 6 | 2019 | 2029 | 0.180 |
Why?
|
| Aldosterone | 3 | 2014 | 877 | 0.180 |
Why?
|
| Blood Circulation | 12 | 1974 | 251 | 0.180 |
Why?
|
| Oxidative Stress | 4 | 2020 | 3086 | 0.180 |
Why?
|
| Glycine | 1 | 2003 | 671 | 0.180 |
Why?
|
| Anistreplase | 2 | 1997 | 12 | 0.180 |
Why?
|
| American Heart Association | 3 | 2019 | 1056 | 0.180 |
Why?
|
| Logistic Models | 20 | 2019 | 13408 | 0.180 |
Why?
|
| Drug Therapy | 3 | 2021 | 497 | 0.180 |
Why?
|
| Dopamine | 7 | 2013 | 1591 | 0.180 |
Why?
|
| Angina Pectoris, Variant | 8 | 1983 | 55 | 0.170 |
Why?
|
| Sarcomeres | 2 | 2019 | 374 | 0.170 |
Why?
|
| Carbazoles | 1 | 2001 | 226 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 365 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2018 | 550 | 0.170 |
Why?
|
| Retrospective Studies | 35 | 2022 | 77449 | 0.170 |
Why?
|
| Leukocytosis | 2 | 2019 | 247 | 0.170 |
Why?
|
| Prevalence | 9 | 2019 | 15226 | 0.170 |
Why?
|
| Body Weight | 12 | 2024 | 4669 | 0.170 |
Why?
|
| Drug Evaluation | 17 | 1992 | 647 | 0.170 |
Why?
|
| Random Allocation | 13 | 2002 | 2429 | 0.170 |
Why?
|
| Death, Sudden | 6 | 2012 | 302 | 0.170 |
Why?
|
| Patient Compliance | 4 | 2010 | 2684 | 0.170 |
Why?
|
| Nitrites | 2 | 2018 | 160 | 0.170 |
Why?
|
| Pressoreceptors | 11 | 1976 | 100 | 0.170 |
Why?
|
| Reference Values | 7 | 2008 | 4982 | 0.160 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2020 | 125 | 0.160 |
Why?
|
| Societies | 1 | 2019 | 104 | 0.160 |
Why?
|
| Percussion | 1 | 2018 | 18 | 0.160 |
Why?
|
| Perfusion | 15 | 1993 | 1360 | 0.160 |
Why?
|
| Mutation | 5 | 2019 | 29786 | 0.160 |
Why?
|
| Radionuclide Imaging | 15 | 2004 | 2031 | 0.160 |
Why?
|
| Auscultation | 1 | 2018 | 42 | 0.160 |
Why?
|
| Amiodarone | 2 | 2015 | 212 | 0.160 |
Why?
|
| Cyclic GMP | 1 | 2019 | 409 | 0.160 |
Why?
|
| Coronary Vasospasm | 3 | 1983 | 88 | 0.160 |
Why?
|
| Heart Function Tests | 15 | 2004 | 330 | 0.160 |
Why?
|
| Metoprolol | 2 | 2016 | 93 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2023 | 817 | 0.160 |
Why?
|
| Palpation | 1 | 2018 | 167 | 0.160 |
Why?
|
| Adolescent | 47 | 2023 | 85781 | 0.160 |
Why?
|
| Placebo Effect | 3 | 2017 | 502 | 0.160 |
Why?
|
| Angioplasty, Balloon | 5 | 1989 | 653 | 0.150 |
Why?
|
| Quinazolines | 6 | 1986 | 1356 | 0.150 |
Why?
|
| Nobel Prize | 1 | 2018 | 49 | 0.150 |
Why?
|
| Angiocardiography | 19 | 1973 | 162 | 0.150 |
Why?
|
| Monocytes | 1 | 2007 | 2596 | 0.150 |
Why?
|
| Drug Utilization | 3 | 2019 | 1183 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2019 | 207 | 0.150 |
Why?
|
| Regression Analysis | 13 | 2009 | 6459 | 0.150 |
Why?
|
| Methoxamine | 12 | 1985 | 45 | 0.150 |
Why?
|
| Glucose | 9 | 2022 | 4397 | 0.150 |
Why?
|
| Genotype | 11 | 2017 | 12951 | 0.150 |
Why?
|
| Probability | 7 | 2010 | 2505 | 0.150 |
Why?
|
| Anesthesiology | 1 | 2007 | 1060 | 0.150 |
Why?
|
| Muscular Diseases | 2 | 2017 | 556 | 0.150 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 61 | 0.150 |
Why?
|
| Triage | 2 | 2001 | 976 | 0.150 |
Why?
|
| Brain Ischemia | 4 | 2016 | 3265 | 0.140 |
Why?
|
| Nitrates | 2 | 2017 | 265 | 0.140 |
Why?
|
| Catecholamines | 7 | 1982 | 387 | 0.140 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2017 | 110 | 0.140 |
Why?
|
| Famous Persons | 1 | 2018 | 108 | 0.140 |
Why?
|
| Education, Medical | 2 | 2008 | 1721 | 0.140 |
Why?
|
| Cardiac Volume | 14 | 1985 | 210 | 0.140 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 684 | 0.140 |
Why?
|
| Placebos | 7 | 2019 | 1676 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2024 | 17446 | 0.140 |
Why?
|
| Fibrosis | 2 | 2021 | 2029 | 0.140 |
Why?
|
| Diagnosis, Differential | 8 | 2013 | 12959 | 0.140 |
Why?
|
| Italy | 2 | 2011 | 832 | 0.140 |
Why?
|
| Dobutamine | 3 | 1986 | 123 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 3 | 2015 | 935 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2019 | 592 | 0.140 |
Why?
|
| Rhabdomyolysis | 1 | 2017 | 150 | 0.140 |
Why?
|
| Body Mass Index | 9 | 2024 | 12720 | 0.130 |
Why?
|
| Research Support as Topic | 3 | 2014 | 705 | 0.130 |
Why?
|
| Tachycardia, Ventricular | 3 | 2011 | 1273 | 0.130 |
Why?
|
| Glyburide | 1 | 2016 | 113 | 0.130 |
Why?
|
| Seasons | 1 | 2001 | 1493 | 0.130 |
Why?
|
| Rats, Inbred Strains | 11 | 1991 | 2186 | 0.130 |
Why?
|
| Hemofiltration | 2 | 2014 | 57 | 0.130 |
Why?
|
| Aorta | 15 | 1979 | 2061 | 0.130 |
Why?
|
| Papillary Muscles | 12 | 1972 | 203 | 0.130 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 19905 | 0.130 |
Why?
|
| Smoking | 10 | 2010 | 8987 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2001 | 536 | 0.130 |
Why?
|
| Receptors, Purinergic P2Y12 | 3 | 2011 | 132 | 0.130 |
Why?
|
| New York | 1 | 2018 | 886 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 20129 | 0.130 |
Why?
|
| Adenosine Triphosphate | 15 | 1987 | 2025 | 0.130 |
Why?
|
| Sensitivity and Specificity | 9 | 2014 | 14722 | 0.130 |
Why?
|
| Case-Control Studies | 10 | 2019 | 21746 | 0.130 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 204 | 0.130 |
Why?
|
| Clinical Protocols | 3 | 2016 | 1462 | 0.130 |
Why?
|
| Adenosine Diphosphate | 4 | 2011 | 425 | 0.130 |
Why?
|
| Apolipoproteins E | 1 | 2000 | 1438 | 0.130 |
Why?
|
| Recreation | 1 | 2015 | 115 | 0.120 |
Why?
|
| Milrinone | 11 | 1991 | 84 | 0.120 |
Why?
|
| Ethanolamines | 4 | 1981 | 158 | 0.120 |
Why?
|
| Ancillary Services, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cats | 17 | 1999 | 998 | 0.120 |
Why?
|
| Physicians, Women | 1 | 2001 | 486 | 0.120 |
Why?
|
| Blood Volume | 8 | 1991 | 565 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 2 | 2018 | 1344 | 0.120 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 1991 | 215 | 0.120 |
Why?
|
| Emergency Medical Services | 4 | 2011 | 1917 | 0.120 |
Why?
|
| Ferritins | 1 | 2017 | 590 | 0.120 |
Why?
|
| Rest | 7 | 2014 | 901 | 0.120 |
Why?
|
| Ventricular Function, Right | 2 | 2017 | 591 | 0.120 |
Why?
|
| Periodicals as Topic | 5 | 2016 | 1432 | 0.120 |
Why?
|
| Epidemiologic Methods | 3 | 2008 | 1364 | 0.120 |
Why?
|
| Natriuretic Agents | 1 | 2013 | 25 | 0.120 |
Why?
|
| Monitoring, Physiologic | 2 | 2001 | 1738 | 0.120 |
Why?
|
| Transplantation, Heterologous | 1 | 2022 | 2382 | 0.120 |
Why?
|
| Glycopeptides | 2 | 2014 | 224 | 0.120 |
Why?
|
| Metabolism | 10 | 1965 | 196 | 0.120 |
Why?
|
| Pharmacology | 10 | 1965 | 103 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 642 | 0.120 |
Why?
|
| Indomethacin | 3 | 1984 | 332 | 0.120 |
Why?
|
| CD40 Ligand | 2 | 2007 | 526 | 0.120 |
Why?
|
| Medicare | 1 | 2012 | 6566 | 0.120 |
Why?
|
| RNA Interference | 1 | 2022 | 2889 | 0.120 |
Why?
|
| Biological Assay | 2 | 2015 | 652 | 0.120 |
Why?
|
| Emergency Service, Hospital | 4 | 2012 | 7659 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2020 | 3336 | 0.120 |
Why?
|
| Receptors, Adrenergic | 5 | 1986 | 155 | 0.120 |
Why?
|
| Hospital Mortality | 7 | 2007 | 5317 | 0.120 |
Why?
|
| Device Removal | 1 | 2019 | 656 | 0.120 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 1991 | 336 | 0.120 |
Why?
|
| Thrombophilia | 1 | 2016 | 305 | 0.110 |
Why?
|
| Heart Rupture, Post-Infarction | 3 | 1990 | 49 | 0.110 |
Why?
|
| ROC Curve | 5 | 2019 | 3527 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.110 |
Why?
|
| Chronic Disease | 14 | 2021 | 9146 | 0.110 |
Why?
|
| Radiography | 9 | 2010 | 7023 | 0.110 |
Why?
|
| Models, Cardiovascular | 2 | 2000 | 996 | 0.110 |
Why?
|
| Proteinuria | 2 | 2006 | 658 | 0.110 |
Why?
|
| Electrophysiology | 5 | 2007 | 1308 | 0.110 |
Why?
|
| Catheterization | 5 | 2012 | 1470 | 0.110 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 238 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2011 | 314 | 0.110 |
Why?
|
| Coronary Stenosis | 3 | 2010 | 834 | 0.110 |
Why?
|
| Prodrugs | 3 | 2009 | 268 | 0.110 |
Why?
|
| Ultrafiltration | 1 | 2012 | 57 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2016 | 1792 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2000 | 1536 | 0.110 |
Why?
|
| Mitral Valve Stenosis | 13 | 2000 | 376 | 0.110 |
Why?
|
| Adrenergic beta-Agonists | 4 | 1981 | 346 | 0.110 |
Why?
|
| Pilot Projects | 11 | 2011 | 8324 | 0.110 |
Why?
|
| Up-Regulation | 6 | 2018 | 4217 | 0.110 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 216 | 0.110 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 55 | 0.100 |
Why?
|
| Metformin | 1 | 2019 | 835 | 0.100 |
Why?
|
| Patient Readmission | 6 | 2016 | 3114 | 0.100 |
Why?
|
| Phosphocreatine | 7 | 1986 | 269 | 0.100 |
Why?
|
| Postoperative Complications | 12 | 2018 | 15295 | 0.100 |
Why?
|
| History, 17th Century | 1 | 2012 | 111 | 0.100 |
Why?
|
| Ventricular Fibrillation | 4 | 2012 | 538 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 1997 | 1011 | 0.100 |
Why?
|
| Allopurinol | 1 | 2013 | 191 | 0.100 |
Why?
|
| Atropine | 14 | 1974 | 244 | 0.100 |
Why?
|
| Purines | 4 | 2013 | 594 | 0.100 |
Why?
|
| Aminophylline | 2 | 1981 | 40 | 0.100 |
Why?
|
| Phenotype | 3 | 2019 | 16365 | 0.100 |
Why?
|
| Adrenomedullin | 1 | 2011 | 87 | 0.100 |
Why?
|
| Aminopyridines | 5 | 1986 | 542 | 0.100 |
Why?
|
| Recovery of Function | 3 | 2019 | 2925 | 0.100 |
Why?
|
| Heart Block | 9 | 1971 | 410 | 0.100 |
Why?
|
| History, Ancient | 1 | 2012 | 212 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2014 | 281 | 0.100 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2011 | 31 | 0.100 |
Why?
|
| Vasomotor System | 6 | 1986 | 209 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2016 | 451 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 5 | 2008 | 2716 | 0.100 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 176 | 0.100 |
Why?
|
| Blood Proteins | 3 | 2014 | 1124 | 0.100 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 149 | 0.100 |
Why?
|
| Time | 3 | 2003 | 542 | 0.100 |
Why?
|
| Factor X | 1 | 2011 | 64 | 0.100 |
Why?
|
| North America | 4 | 2019 | 1249 | 0.100 |
Why?
|
| Pulsatile Flow | 2 | 2004 | 332 | 0.100 |
Why?
|
| Obesity, Morbid | 2 | 2016 | 1213 | 0.100 |
Why?
|
| Blood Urea Nitrogen | 2 | 2014 | 191 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2017 | 2634 | 0.100 |
Why?
|
| Diastole | 3 | 2017 | 791 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2020 | 1859 | 0.090 |
Why?
|
| Assisted Circulation | 7 | 1978 | 103 | 0.090 |
Why?
|
| Phonocardiography | 7 | 1982 | 34 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1130 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2017 | 985 | 0.090 |
Why?
|
| Internal Medicine | 2 | 1991 | 1009 | 0.090 |
Why?
|
| Obesity | 5 | 2024 | 12745 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2010 | 57 | 0.090 |
Why?
|
| Methods | 16 | 1983 | 1129 | 0.090 |
Why?
|
| Bacteria | 1 | 2021 | 2114 | 0.090 |
Why?
|
| Organizational Objectives | 1 | 2012 | 438 | 0.090 |
Why?
|
| Fluorocarbons | 4 | 1983 | 452 | 0.090 |
Why?
|
| Mitochondria | 1 | 2023 | 3520 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2011 | 314 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2014 | 775 | 0.090 |
Why?
|
| Young Adult | 8 | 2021 | 56430 | 0.090 |
Why?
|
| Platelet Adhesiveness | 1 | 2010 | 161 | 0.090 |
Why?
|
| Pericarditis | 2 | 1989 | 128 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2013 | 2077 | 0.090 |
Why?
|
| New Zealand | 2 | 2019 | 355 | 0.090 |
Why?
|
| National Socialism | 1 | 2010 | 53 | 0.090 |
Why?
|
| Motor Activity | 2 | 2017 | 2714 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 6 | 1981 | 174 | 0.090 |
Why?
|
| Nitroprusside | 6 | 1986 | 275 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 2538 | 0.090 |
Why?
|
| Methylprednisolone | 3 | 1983 | 387 | 0.090 |
Why?
|
| Health Services Accessibility | 3 | 2002 | 5137 | 0.090 |
Why?
|
| Heart Rupture | 1 | 1989 | 23 | 0.090 |
Why?
|
| Drug Design | 1 | 2015 | 1076 | 0.090 |
Why?
|
| Genetic Variation | 4 | 2015 | 6544 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2011 | 169 | 0.090 |
Why?
|
| Statistics, Nonparametric | 6 | 2009 | 2886 | 0.090 |
Why?
|
| Vocational Guidance | 1 | 2008 | 13 | 0.080 |
Why?
|
| South America | 2 | 2019 | 181 | 0.080 |
Why?
|
| Models, Biological | 6 | 2013 | 9583 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2014 | 575 | 0.080 |
Why?
|
| Calcium Channels | 1 | 2013 | 622 | 0.080 |
Why?
|
| Diltiazem | 3 | 1992 | 133 | 0.080 |
Why?
|
| Environmental Exposure | 2 | 2023 | 4234 | 0.080 |
Why?
|
| Treatment Failure | 5 | 2018 | 2618 | 0.080 |
Why?
|
| Rats | 25 | 1991 | 24260 | 0.080 |
Why?
|
| Mitral Valve Insufficiency | 12 | 2000 | 1422 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 4 | 2003 | 235 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2011 | 786 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 4186 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1889 | 0.080 |
Why?
|
| Parasympathetic Nervous System | 5 | 1974 | 141 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 4420 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 1987 | 246 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2016 | 1062 | 0.080 |
Why?
|
| Mesenteric Arteries | 9 | 1974 | 183 | 0.080 |
Why?
|
| Hyperthyroidism | 4 | 1979 | 295 | 0.080 |
Why?
|
| Pandemics | 3 | 2020 | 8388 | 0.080 |
Why?
|
| Proteomics | 1 | 2021 | 3638 | 0.080 |
Why?
|
| Stimulation, Chemical | 8 | 1986 | 326 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2016 | 1099 | 0.080 |
Why?
|
| Vitamin K | 1 | 2010 | 295 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 13989 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 2418 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2016 | 1058 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3870 | 0.080 |
Why?
|
| Confidence Intervals | 4 | 2010 | 2971 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2017 | 3200 | 0.080 |
Why?
|
| Knowledge Bases | 1 | 2007 | 85 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 1475 | 0.080 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2007 | 54 | 0.080 |
Why?
|
| Prediabetic State | 1 | 2013 | 499 | 0.080 |
Why?
|
| Calgranulin A | 1 | 2007 | 79 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 891 | 0.070 |
Why?
|
| Flurbiprofen | 3 | 1981 | 21 | 0.070 |
Why?
|
| Starlings | 6 | 1964 | 7 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2008 | 197 | 0.070 |
Why?
|
| Calgranulin B | 1 | 2007 | 84 | 0.070 |
Why?
|
| Australia | 2 | 2019 | 1170 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 1997 | 1392 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 404 | 0.070 |
Why?
|
| Ventricular Premature Complexes | 2 | 2010 | 111 | 0.070 |
Why?
|
| Biopsy | 3 | 2017 | 6756 | 0.070 |
Why?
|
| International Normalized Ratio | 3 | 2018 | 367 | 0.070 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2007 | 25 | 0.070 |
Why?
|
| Specialization | 2 | 1991 | 777 | 0.070 |
Why?
|
| Sympatholytics | 6 | 1966 | 83 | 0.070 |
Why?
|
| Heterozygote | 3 | 2008 | 2804 | 0.070 |
Why?
|
| Pulmonary Circulation | 5 | 2024 | 739 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2009 | 419 | 0.070 |
Why?
|
| Prostaglandins | 3 | 1972 | 405 | 0.070 |
Why?
|
| Ventricular Pressure | 4 | 2017 | 199 | 0.070 |
Why?
|
| Lymphocytes | 3 | 2023 | 2617 | 0.070 |
Why?
|
| Drug Tolerance | 6 | 1986 | 376 | 0.070 |
Why?
|
| Writing | 1 | 2008 | 206 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2020 | 964 | 0.070 |
Why?
|
| Helminth Proteins | 1 | 2007 | 171 | 0.070 |
Why?
|
| Europe, Eastern | 2 | 2023 | 75 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2219 | 0.070 |
Why?
|
| Hydrocortisone | 7 | 1978 | 1826 | 0.070 |
Why?
|
| Coronary Restenosis | 2 | 2008 | 424 | 0.070 |
Why?
|
| Age Distribution | 3 | 2017 | 2902 | 0.070 |
Why?
|
| Injections | 3 | 2002 | 840 | 0.070 |
Why?
|
| Microcirculation | 7 | 2006 | 1286 | 0.070 |
Why?
|
| Carbon Dioxide | 6 | 1980 | 1150 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2006 | 203 | 0.070 |
Why?
|
| Iliac Artery | 8 | 1974 | 364 | 0.070 |
Why?
|
| Inpatients | 2 | 2012 | 2518 | 0.070 |
Why?
|
| Aryldialkylphosphatase | 1 | 2005 | 63 | 0.070 |
Why?
|
| Area Under Curve | 3 | 2011 | 1654 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2011 | 850 | 0.070 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2006 | 127 | 0.070 |
Why?
|
| Models, Statistical | 3 | 2010 | 5102 | 0.070 |
Why?
|
| Reserpine | 7 | 1981 | 66 | 0.070 |
Why?
|
| Collateral Circulation | 3 | 2001 | 287 | 0.070 |
Why?
|
| Pulmonary Valve Stenosis | 6 | 1974 | 183 | 0.070 |
Why?
|
| Elasticity | 7 | 1991 | 657 | 0.060 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3133 | 0.060 |
Why?
|
| Systole | 3 | 1985 | 958 | 0.060 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3240 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 841 | 0.060 |
Why?
|
| Argentina | 1 | 2015 | 232 | 0.060 |
Why?
|
| Educational Status | 1 | 1993 | 2540 | 0.060 |
Why?
|
| Certification | 1 | 2008 | 424 | 0.060 |
Why?
|
| Biliopancreatic Diversion | 1 | 2004 | 16 | 0.060 |
Why?
|
| Stem Cells | 1 | 2018 | 3567 | 0.060 |
Why?
|
| Hydroxyproline | 5 | 1985 | 116 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 1534 | 0.060 |
Why?
|
| Job Satisfaction | 1 | 2008 | 535 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 1405 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2004 | 629 | 0.060 |
Why?
|
| Guanethidine | 4 | 1965 | 15 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 2866 | 0.060 |
Why?
|
| Microscopy, Electron | 8 | 1983 | 2645 | 0.060 |
Why?
|
| Timolol | 1 | 1984 | 52 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 3229 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2016 | 1590 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 526 | 0.060 |
Why?
|
| Enzymes | 1 | 2006 | 266 | 0.060 |
Why?
|
| Asia | 2 | 2019 | 610 | 0.060 |
Why?
|
| Decision Trees | 2 | 2001 | 506 | 0.060 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2005 | 194 | 0.060 |
Why?
|
| Technetium | 4 | 1980 | 334 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 1991 | 1827 | 0.060 |
Why?
|
| Metals | 1 | 2009 | 719 | 0.060 |
Why?
|
| Arteriosclerosis | 4 | 1998 | 1092 | 0.060 |
Why?
|
| Ligation | 8 | 1984 | 453 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2011 | 1403 | 0.060 |
Why?
|
| Emergencies | 2 | 2001 | 1170 | 0.060 |
Why?
|
| Case Management | 1 | 2006 | 286 | 0.060 |
Why?
|
| Immunoassay | 3 | 2010 | 752 | 0.060 |
Why?
|
| Heart Septal Defects, Ventricular | 6 | 1970 | 488 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha | 3 | 1981 | 149 | 0.060 |
Why?
|
| Renal Artery | 7 | 1974 | 398 | 0.060 |
Why?
|
| Acetates | 2 | 2011 | 311 | 0.060 |
Why?
|
| Speech | 1 | 2008 | 540 | 0.060 |
Why?
|
| Premedication | 1 | 2004 | 258 | 0.060 |
Why?
|
| Blood Pressure Determination | 9 | 1972 | 634 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1152 | 0.060 |
Why?
|
| Amrinone | 5 | 1986 | 14 | 0.060 |
Why?
|
| Disease Management | 3 | 2003 | 2459 | 0.060 |
Why?
|
| Medicine | 2 | 1991 | 946 | 0.060 |
Why?
|
| Sodium Channel Blockers | 2 | 2014 | 176 | 0.060 |
Why?
|
| African Americans | 1 | 2002 | 23 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 25043 | 0.060 |
Why?
|
| Cicatrix | 3 | 1990 | 764 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 426 | 0.060 |
Why?
|
| Gastroplasty | 1 | 2004 | 142 | 0.050 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 1979 | 0.050 |
Why?
|
| Organ Size | 6 | 1991 | 2252 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2006 | 559 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 1602 | 0.050 |
Why?
|
| Pulse | 8 | 1985 | 229 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2006 | 413 | 0.050 |
Why?
|
| Heart Septal Defects | 4 | 1965 | 192 | 0.050 |
Why?
|
| Calcinosis | 3 | 2005 | 1499 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 838 | 0.050 |
Why?
|
| Infusions, Parenteral | 6 | 1986 | 419 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1316 | 0.050 |
Why?
|
| Ion Channels | 3 | 1982 | 1056 | 0.050 |
Why?
|
| Health Status | 4 | 2019 | 4034 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2017 | 2297 | 0.050 |
Why?
|
| Patient Admission | 2 | 2001 | 1380 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12261 | 0.050 |
Why?
|
| Sodium | 4 | 2014 | 1623 | 0.050 |
Why?
|
| Perhexiline | 1 | 1980 | 5 | 0.050 |
Why?
|
| Benzofurans | 1 | 1982 | 140 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2002 | 241 | 0.050 |
Why?
|
| Ibuprofen | 1 | 1983 | 236 | 0.050 |
Why?
|
| Outpatients | 3 | 2014 | 1486 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 1486 | 0.050 |
Why?
|
| Angiography | 7 | 2002 | 1639 | 0.050 |
Why?
|
| Latin America | 2 | 2018 | 381 | 0.050 |
Why?
|
| Overweight | 3 | 2019 | 2371 | 0.050 |
Why?
|
| Fibrinolysis | 3 | 2010 | 322 | 0.050 |
Why?
|
| Constriction, Pathologic | 13 | 1994 | 1107 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 199 | 0.050 |
Why?
|
| Mitral Valve | 8 | 1997 | 1491 | 0.050 |
Why?
|
| Emergency Medicine | 1 | 2010 | 1207 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6895 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4456 | 0.050 |
Why?
|
| Linear Models | 4 | 2012 | 5952 | 0.050 |
Why?
|
| Survivors | 2 | 2008 | 2291 | 0.050 |
Why?
|
| Bundle-Branch Block | 4 | 1988 | 270 | 0.050 |
Why?
|
| Demography | 2 | 2003 | 1656 | 0.050 |
Why?
|
| Motivation | 2 | 2008 | 1971 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2011 | 1972 | 0.050 |
Why?
|
| Propionates | 1 | 1981 | 169 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 1741 | 0.050 |
Why?
|
| Sirolimus | 1 | 2007 | 1564 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2007 | 1708 | 0.050 |
Why?
|
| Body Constitution | 1 | 2000 | 278 | 0.050 |
Why?
|
| Nadroparin | 1 | 1999 | 3 | 0.050 |
Why?
|
| Neoplasms | 3 | 2018 | 21683 | 0.050 |
Why?
|
| Phentolamine | 6 | 1981 | 104 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2009 | 2440 | 0.050 |
Why?
|
| Heart Injuries | 2 | 1980 | 210 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1203 | 0.050 |
Why?
|
| Internationality | 2 | 2016 | 1003 | 0.040 |
Why?
|
| Serum Albumin | 3 | 2016 | 676 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2010 | 2616 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2024 | 435 | 0.040 |
Why?
|
| P-Selectin | 2 | 2000 | 600 | 0.040 |
Why?
|
| Phenylephrine | 6 | 1976 | 301 | 0.040 |
Why?
|
| Dalteparin | 1 | 1999 | 42 | 0.040 |
Why?
|
| Urine | 3 | 2013 | 370 | 0.040 |
Why?
|
| Equipment Design | 1 | 2008 | 3582 | 0.040 |
Why?
|
| Digitalis | 3 | 1964 | 14 | 0.040 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 139 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 3 | 1998 | 2647 | 0.040 |
Why?
|
| Government Agencies | 1 | 2000 | 156 | 0.040 |
Why?
|
| Apolipoprotein C-III | 1 | 2000 | 202 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2002 | 460 | 0.040 |
Why?
|
| Inorganic Chemicals | 1 | 2018 | 10 | 0.040 |
Why?
|
| Geography | 1 | 2001 | 669 | 0.040 |
Why?
|
| Extremities | 2 | 2016 | 865 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 316 | 0.040 |
Why?
|
| France | 2 | 2011 | 517 | 0.040 |
Why?
|
| Tyramine | 4 | 1968 | 52 | 0.040 |
Why?
|
| Disease Models, Animal | 14 | 1985 | 18029 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2009 | 3209 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 1980 | 243 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2022 | 476 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 675 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2002 | 600 | 0.040 |
Why?
|
| Heart Defects, Congenital | 11 | 1984 | 4584 | 0.040 |
Why?
|
| Anemia | 2 | 2005 | 1506 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2014 | 3752 | 0.040 |
Why?
|
| Diet | 2 | 2017 | 7939 | 0.040 |
Why?
|
| Phospholipids | 1 | 2022 | 784 | 0.040 |
Why?
|
| Benzazepines | 1 | 1980 | 326 | 0.040 |
Why?
|
| Ferricyanides | 1 | 1978 | 32 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2022 | 878 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2000 | 371 | 0.040 |
Why?
|
| Strophanthins | 4 | 1969 | 5 | 0.040 |
Why?
|
| Radioisotopes | 3 | 1987 | 499 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 1999 | 666 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
| Length of Stay | 3 | 1998 | 6309 | 0.040 |
Why?
|
| Rheology | 2 | 2000 | 345 | 0.040 |
Why?
|
| Tachycardia, Paroxysmal | 2 | 1969 | 31 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2019 | 124 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2002 | 544 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 661 | 0.040 |
Why?
|
| Biological Availability | 1 | 1998 | 397 | 0.040 |
Why?
|
| Child | 25 | 2019 | 77709 | 0.040 |
Why?
|
| Selection Bias | 2 | 1997 | 371 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 738 | 0.040 |
Why?
|
| Hormones | 1 | 1981 | 889 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2019 | 233 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 1981 | 491 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 6 | 2000 | 579 | 0.040 |
Why?
|
| Vasodilation | 4 | 1986 | 944 | 0.040 |
Why?
|
| Women's Health | 1 | 2007 | 2034 | 0.040 |
Why?
|
| Denervation | 3 | 1976 | 278 | 0.040 |
Why?
|
| Fibrinopeptide A | 1 | 1996 | 44 | 0.040 |
Why?
|
| Walking | 2 | 2015 | 1180 | 0.040 |
Why?
|
| Autoradiography | 3 | 1983 | 745 | 0.040 |
Why?
|
| Serum Albumin, Radio-Iodinated | 3 | 1971 | 37 | 0.040 |
Why?
|
| Arteries | 6 | 1993 | 1119 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2212 | 0.040 |
Why?
|
| Pulmonary Artery | 11 | 1972 | 1912 | 0.040 |
Why?
|
| Protein-Losing Enteropathies | 2 | 1968 | 45 | 0.040 |
Why?
|
| Germany | 1 | 2019 | 862 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2002 | 581 | 0.040 |
Why?
|
| Constriction | 6 | 1981 | 181 | 0.040 |
Why?
|
| Free Radicals | 2 | 1988 | 237 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1730 | 0.040 |
Why?
|
| Antithrombin III | 1 | 1996 | 128 | 0.030 |
Why?
|
| Communication | 2 | 2008 | 3749 | 0.030 |
Why?
|
| Forearm | 3 | 1969 | 409 | 0.030 |
Why?
|
| Prothrombin | 1 | 1996 | 185 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1996 | 177 | 0.030 |
Why?
|
| Transferrin | 1 | 2017 | 295 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 3 | 1985 | 346 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 262 | 0.030 |
Why?
|
| Retreatment | 2 | 2012 | 610 | 0.030 |
Why?
|
| Gastric Bypass | 1 | 2004 | 812 | 0.030 |
Why?
|
| Cytokines | 2 | 2001 | 7322 | 0.030 |
Why?
|
| Muscles | 3 | 1974 | 1614 | 0.030 |
Why?
|
| Niacin | 1 | 2016 | 116 | 0.030 |
Why?
|
| Posture | 5 | 1980 | 958 | 0.030 |
Why?
|
| Long-Term Care | 2 | 2015 | 607 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 1105 | 0.030 |
Why?
|
| Exercise | 4 | 2010 | 5615 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 5 | 1968 | 177 | 0.030 |
Why?
|
| Curriculum | 2 | 2008 | 3605 | 0.030 |
Why?
|
| Brazil | 1 | 2019 | 1270 | 0.030 |
Why?
|
| Health Services | 1 | 1980 | 758 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1987 | 3589 | 0.030 |
Why?
|
| Dilatation | 3 | 1988 | 291 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2018 | 7729 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1980 | 738 | 0.030 |
Why?
|
| Mathematics | 3 | 1985 | 728 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 816 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1995 | 919 | 0.030 |
Why?
|
| Thallium | 2 | 1987 | 101 | 0.030 |
Why?
|
| Weight Loss | 3 | 2012 | 2622 | 0.030 |
Why?
|
| Heart Septal Defects, Atrial | 3 | 1967 | 478 | 0.030 |
Why?
|
| Indicator Dilution Techniques | 2 | 1966 | 40 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1997 | 355 | 0.030 |
Why?
|
| Training Support | 1 | 1975 | 113 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 1998 | 577 | 0.030 |
Why?
|
| Vascular Grafting | 1 | 2016 | 142 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1997 | 845 | 0.030 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2000 | 349 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2016 | 475 | 0.030 |
Why?
|
| Cold Temperature | 3 | 1976 | 772 | 0.030 |
Why?
|
| Limb Salvage | 1 | 2016 | 433 | 0.030 |
Why?
|
| Heart, Artificial | 2 | 1964 | 102 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1995 | 281 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1986 | 2291 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 995 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 1170 | 0.030 |
Why?
|
| Radiography, Thoracic | 3 | 1964 | 1265 | 0.030 |
Why?
|
| Amino Alcohols | 1 | 1973 | 16 | 0.030 |
Why?
|
| Hospital Departments | 1 | 1993 | 137 | 0.030 |
Why?
|
| Polymers | 1 | 1981 | 1621 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2001 | 2751 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 1996 | 634 | 0.030 |
Why?
|
| Adrenergic Agents | 2 | 1963 | 70 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1998 | 1227 | 0.030 |
Why?
|
| Pyridazines | 2 | 1986 | 202 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 81183 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2013 | 265 | 0.030 |
Why?
|
| Rats, Mutant Strains | 2 | 1982 | 70 | 0.030 |
Why?
|
| Platelet Count | 2 | 2006 | 781 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2013 | 154 | 0.030 |
Why?
|
| Depression, Chemical | 4 | 1982 | 191 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 220 | 0.030 |
Why?
|
| Plasminogen | 2 | 1990 | 152 | 0.030 |
Why?
|
| Aorta, Thoracic | 3 | 1971 | 1082 | 0.030 |
Why?
|
| Blood Gas Analysis | 2 | 1982 | 383 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2002 | 5078 | 0.030 |
Why?
|
| Procollagen | 1 | 2012 | 185 | 0.030 |
Why?
|
| Contrast Media | 3 | 2001 | 5300 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 1993 | 263 | 0.030 |
Why?
|
| Kymography | 1 | 1971 | 14 | 0.030 |
Why?
|
| Spectrophotometry | 3 | 1972 | 313 | 0.030 |
Why?
|
| Radar | 1 | 1971 | 11 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2000 | 1736 | 0.030 |
Why?
|
| Radionuclide Ventriculography | 1 | 1991 | 41 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 4462 | 0.030 |
Why?
|
| Pressure | 5 | 1978 | 1203 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 5 | 1988 | 1681 | 0.020 |
Why?
|
| Guinea Pigs | 4 | 1980 | 1386 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 3 | 1990 | 1790 | 0.020 |
Why?
|
| Ultrasonics | 4 | 1974 | 212 | 0.020 |
Why?
|
| Financing, Government | 1 | 1975 | 468 | 0.020 |
Why?
|
| Mitochondria, Heart | 3 | 1982 | 247 | 0.020 |
Why?
|
| Cardiac Care Facilities | 1 | 1990 | 35 | 0.020 |
Why?
|
| Pathology | 2 | 1964 | 272 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 1986 | 177 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 1983 | 219 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 2009 | 2708 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1995 | 3129 | 0.020 |
Why?
|
| Norway | 1 | 2012 | 448 | 0.020 |
Why?
|
| Exercise Therapy | 2 | 1980 | 906 | 0.020 |
Why?
|
| Health Behavior | 1 | 2002 | 2636 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3719 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 1002 | 0.020 |
Why?
|
| Fibrinogen | 2 | 1991 | 894 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 673 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 990 | 0.020 |
Why?
|
| Alleles | 1 | 2001 | 6933 | 0.020 |
Why?
|
| Patients | 2 | 2001 | 900 | 0.020 |
Why?
|
| Brachial Artery | 3 | 1971 | 369 | 0.020 |
Why?
|
| Autonomic Nerve Block | 2 | 1970 | 72 | 0.020 |
Why?
|
| Anesthesia, General | 3 | 1971 | 1171 | 0.020 |
Why?
|
| Cyclic AMP | 2 | 1986 | 1472 | 0.020 |
Why?
|
| Causality | 1 | 2016 | 1275 | 0.020 |
Why?
|
| Fluids and Secretions | 2 | 1965 | 6 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 168 | 0.020 |
Why?
|
| Postmenopause | 1 | 1998 | 2461 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2009 | 173 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 2 | 1968 | 272 | 0.020 |
Why?
|
| Spasm | 2 | 1980 | 121 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 1990 | 162 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 711 | 0.020 |
Why?
|
| Arrhythmia, Sinus | 2 | 1968 | 56 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 796 | 0.020 |
Why?
|
| Pericarditis, Constrictive | 2 | 1968 | 42 | 0.020 |
Why?
|
| Glucagon | 3 | 1986 | 533 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1975 | 719 | 0.020 |
Why?
|
| Action Potentials | 3 | 1982 | 1806 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 1993 | 1179 | 0.020 |
Why?
|
| Fasting | 1 | 2015 | 1593 | 0.020 |
Why?
|
| Bradycardia | 2 | 1986 | 307 | 0.020 |
Why?
|
| Dye Dilution Technique | 2 | 1967 | 17 | 0.020 |
Why?
|
| Vena Cava, Inferior | 4 | 1974 | 440 | 0.020 |
Why?
|
| Prosthesis Design | 2 | 2009 | 2110 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 1990 | 348 | 0.020 |
Why?
|
| Nerve Endings | 2 | 1968 | 109 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7880 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2016 | 1158 | 0.020 |
Why?
|
| Epinephrine | 3 | 1974 | 792 | 0.020 |
Why?
|
| Plethysmography | 2 | 1968 | 180 | 0.020 |
Why?
|
| Phenoxybenzamine | 2 | 1981 | 54 | 0.020 |
Why?
|
| Receptors, Lipoprotein | 1 | 1988 | 81 | 0.020 |
Why?
|
| Leukopenia | 1 | 1968 | 212 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 611 | 0.020 |
Why?
|
| Thrombophlebitis | 2 | 1968 | 309 | 0.020 |
Why?
|
| Eating | 1 | 1974 | 1536 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3679 | 0.020 |
Why?
|
| Massachusetts | 2 | 2014 | 8663 | 0.020 |
Why?
|
| Progesterone Congeners | 1 | 2007 | 42 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 12072 | 0.020 |
Why?
|
| Lidocaine | 1 | 1990 | 544 | 0.020 |
Why?
|
| Electric Countershock | 2 | 1973 | 534 | 0.020 |
Why?
|
| Pulmonary Embolism | 3 | 1988 | 2376 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2007 | 264 | 0.020 |
Why?
|
| Telemetry | 3 | 1972 | 205 | 0.020 |
Why?
|
| Hypothyroidism | 2 | 1969 | 658 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 7181 | 0.020 |
Why?
|
| Tricuspid Valve | 2 | 1972 | 403 | 0.020 |
Why?
|
| Uric Acid | 1 | 2012 | 766 | 0.020 |
Why?
|
| Cardanolides | 4 | 1971 | 4 | 0.020 |
Why?
|
| Synaptic Transmission | 2 | 1974 | 1178 | 0.020 |
Why?
|
| Radiometry | 2 | 1962 | 800 | 0.020 |
Why?
|
| Mitochondria, Muscle | 3 | 1974 | 171 | 0.020 |
Why?
|
| Oxyfedrine | 1 | 1986 | 1 | 0.020 |
Why?
|
| Enoximone | 1 | 1986 | 9 | 0.020 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1986 | 36 | 0.020 |
Why?
|
| Decision Making | 1 | 2000 | 3887 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2013 | 1092 | 0.020 |
Why?
|
| Valsalva Maneuver | 3 | 1970 | 92 | 0.020 |
Why?
|
| Vectorcardiography | 2 | 1956 | 43 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1986 | 57 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2000 | 23403 | 0.020 |
Why?
|
| Life Style | 1 | 2017 | 3835 | 0.020 |
Why?
|
| Xanthines | 1 | 1986 | 121 | 0.020 |
Why?
|
| Theophylline | 1 | 1986 | 132 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 1150 | 0.020 |
Why?
|
| Reoperation | 1 | 1995 | 4201 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2017 | 2063 | 0.020 |
Why?
|
| Pentobarbital | 3 | 1971 | 155 | 0.020 |
Why?
|
| Infant | 7 | 2021 | 35136 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 2 | 1980 | 264 | 0.020 |
Why?
|
| Coenzymes | 1 | 1986 | 91 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 4256 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 1257 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 3002 | 0.020 |
Why?
|
| Anaerobiosis | 2 | 1976 | 140 | 0.020 |
Why?
|
| Vagotomy | 1 | 1965 | 83 | 0.020 |
Why?
|
| Amyl Nitrite | 1 | 1964 | 9 | 0.020 |
Why?
|
| Hypoxanthines | 2 | 1984 | 35 | 0.020 |
Why?
|
| Levodopa | 1 | 1986 | 219 | 0.020 |
Why?
|
| Respiration | 3 | 1969 | 1653 | 0.020 |
Why?
|
| Chromatography | 1 | 1964 | 206 | 0.020 |
Why?
|
| Calcium Chloride | 1 | 1964 | 77 | 0.020 |
Why?
|
| Oklahoma | 1 | 2004 | 37 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 892 | 0.020 |
Why?
|
| Blood Vessels | 3 | 1982 | 1125 | 0.020 |
Why?
|
| Mephentermine | 2 | 1961 | 6 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 1460 | 0.020 |
Why?
|
| Glycogen | 3 | 1978 | 260 | 0.020 |
Why?
|
| Heart Auscultation | 1 | 1964 | 37 | 0.020 |
Why?
|
| Ubiquinone | 1 | 1986 | 188 | 0.020 |
Why?
|
| Sensory Receptor Cells | 2 | 1970 | 492 | 0.020 |
Why?
|
| Tritium | 1 | 1964 | 745 | 0.020 |
Why?
|
| Autonomic Nervous System | 2 | 1971 | 671 | 0.020 |
Why?
|
| Metaraminol | 1 | 1963 | 8 | 0.020 |
Why?
|
| Apoptosis | 1 | 2000 | 9727 | 0.020 |
Why?
|
| Hemothorax | 1 | 1964 | 60 | 0.020 |
Why?
|
| Photomicrography | 1 | 1964 | 74 | 0.020 |
Why?
|
| Histamine | 1 | 1986 | 507 | 0.010 |
Why?
|
| Minoxidil | 1 | 1984 | 33 | 0.010 |
Why?
|
| Neurochemistry | 1 | 1963 | 29 | 0.010 |
Why?
|
| Situs Inversus | 1 | 1964 | 64 | 0.010 |
Why?
|
| Inosine | 2 | 1984 | 133 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1184 | 0.010 |
Why?
|
| Transferases | 1 | 1963 | 75 | 0.010 |
Why?
|
| Neurophysiology | 1 | 1964 | 142 | 0.010 |
Why?
|
| Hemostasis | 2 | 1996 | 458 | 0.010 |
Why?
|
| Biochemical Phenomena | 1 | 1963 | 59 | 0.010 |
Why?
|
| Embolism, Air | 1 | 1964 | 111 | 0.010 |
Why?
|
| Postoperative Period | 2 | 1986 | 1842 | 0.010 |
Why?
|
| Disease | 3 | 1958 | 680 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 2 | 1978 | 875 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 1681 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 1977 | 367 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 1963 | 178 | 0.010 |
Why?
|
| Tricuspid Valve Stenosis | 1 | 1963 | 32 | 0.010 |
Why?
|
| SRS-A | 1 | 1983 | 156 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1990 | 1312 | 0.010 |
Why?
|
| Reference Standards | 1 | 2007 | 1025 | 0.010 |
Why?
|
| Endocardium | 2 | 1983 | 263 | 0.010 |
Why?
|
| Tricuspid Atresia | 1 | 1963 | 36 | 0.010 |
Why?
|
| Anesthesia | 2 | 1972 | 1561 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 613 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2009 | 1184 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 2 | 2000 | 193 | 0.010 |
Why?
|
| Biochemistry | 1 | 1963 | 113 | 0.010 |
Why?
|
| Albumins | 2 | 1980 | 569 | 0.010 |
Why?
|
| Fees, Pharmaceutical | 1 | 2002 | 64 | 0.010 |
Why?
|
| Heart Sounds | 1 | 1962 | 20 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2012 | 3420 | 0.010 |
Why?
|
| Residual Volume | 1 | 1962 | 41 | 0.010 |
Why?
|
| Adenosine Monophosphate | 2 | 1984 | 275 | 0.010 |
Why?
|
| Glutamine | 1 | 2005 | 578 | 0.010 |
Why?
|
| Magnetics | 3 | 1970 | 606 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1983 | 382 | 0.010 |
Why?
|
| Fluorescence | 1 | 1964 | 751 | 0.010 |
Why?
|
| Hepatitis | 1 | 1964 | 227 | 0.010 |
Why?
|
| Data Collection | 2 | 2001 | 3341 | 0.010 |
Why?
|
| Immunity | 1 | 1968 | 1012 | 0.010 |
Why?
|
| Chest Pain | 1 | 2009 | 1114 | 0.010 |
Why?
|
| Teprotide | 1 | 1981 | 28 | 0.010 |
Why?
|
| Pulmonary Valve | 1 | 1966 | 437 | 0.010 |
Why?
|
| Drug Costs | 1 | 2009 | 1105 | 0.010 |
Why?
|
| Thorax | 3 | 1978 | 547 | 0.010 |
Why?
|
| Artificial Organs | 1 | 1964 | 204 | 0.010 |
Why?
|
| Hydralazine | 1 | 1981 | 38 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 944 | 0.010 |
Why?
|
| Antigens, Human Platelet | 1 | 2001 | 43 | 0.010 |
Why?
|
| Genetics, Medical | 1 | 1964 | 338 | 0.010 |
Why?
|
| Sodium, Dietary | 1 | 1965 | 418 | 0.010 |
Why?
|
| Ergonovine | 1 | 1981 | 15 | 0.010 |
Why?
|
| Critical Care | 1 | 1994 | 2647 | 0.010 |
Why?
|
| Biological Transport | 2 | 1982 | 2118 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1981 | 91 | 0.010 |
Why?
|
| Concurrent Review | 1 | 1980 | 13 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1984 | 1144 | 0.010 |
Why?
|
| Tetralogy of Fallot | 2 | 1964 | 623 | 0.010 |
Why?
|
| Employee Incentive Plans | 1 | 1980 | 15 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1980 | 115 | 0.010 |
Why?
|
| Preoperative Care | 3 | 1980 | 2250 | 0.010 |
Why?
|
| Polarography | 2 | 1971 | 10 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1986 | 632 | 0.010 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1962 | 162 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13815 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 1785 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2008 | 3588 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 1981 | 110 | 0.010 |
Why?
|
| Partial Pressure | 3 | 1979 | 254 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1964 | 513 | 0.010 |
Why?
|
| Veins | 2 | 1966 | 770 | 0.010 |
Why?
|
| Sulfinpyrazone | 1 | 1980 | 14 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1980 | 5788 | 0.010 |
Why?
|
| Hematocrit | 1 | 1982 | 636 | 0.010 |
Why?
|
| Oximetry | 3 | 1970 | 471 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1987 | 1547 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 18111 | 0.010 |
Why?
|
| Hot Temperature | 2 | 1981 | 1354 | 0.010 |
Why?
|
| Estrogens | 1 | 2007 | 1566 | 0.010 |
Why?
|
| Imidazoles | 1 | 1986 | 1206 | 0.010 |
Why?
|
| Energy Metabolism | 2 | 1981 | 2899 | 0.010 |
Why?
|
| Nitrogen | 1 | 1980 | 344 | 0.010 |
Why?
|
| Child, Preschool | 11 | 1972 | 41006 | 0.010 |
Why?
|
| Transposition of Great Vessels | 1 | 1964 | 588 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2013 | 3864 | 0.010 |
Why?
|
| Glycolysis | 2 | 1974 | 827 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 2 | 1974 | 481 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1988 | 2132 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2010 | 15519 | 0.010 |
Why?
|
| Biological Products | 1 | 1988 | 860 | 0.010 |
Why?
|
| Hypertrophy | 2 | 1972 | 569 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 3479 | 0.010 |
Why?
|
| Feces | 1 | 1964 | 1401 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1981 | 2255 | 0.010 |
Why?
|
| Electricity | 2 | 1969 | 182 | 0.010 |
Why?
|
| Sphygmomanometers | 1 | 1997 | 15 | 0.010 |
Why?
|
| Ileum | 1 | 1981 | 565 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2010 | 2071 | 0.010 |
Why?
|
| Sleep | 2 | 1971 | 4623 | 0.010 |
Why?
|
| Lipid Metabolism | 2 | 1980 | 1889 | 0.010 |
Why?
|
| Electrodes, Implanted | 2 | 1974 | 824 | 0.010 |
Why?
|
| Particle Size | 1 | 1982 | 1642 | 0.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1978 | 85 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1981 | 597 | 0.010 |
Why?
|
| Mitochondrial Swelling | 2 | 1978 | 17 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1799 | 0.010 |
Why?
|
| Pregnancy | 3 | 2012 | 29144 | 0.010 |
Why?
|
| Endothelium | 1 | 1980 | 778 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 8436 | 0.010 |
Why?
|
| Acetylcholine | 2 | 1971 | 621 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2009 | 1905 | 0.010 |
Why?
|
| Extracorporeal Circulation | 2 | 1968 | 182 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1964 | 742 | 0.010 |
Why?
|
| Atrial Appendage | 1 | 1961 | 283 | 0.010 |
Why?
|
| Mannitol | 1 | 1978 | 181 | 0.010 |
Why?
|
| Carotid Arteries | 2 | 1972 | 952 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1977 | 117 | 0.010 |
Why?
|
| Testis | 1 | 1981 | 803 | 0.010 |
Why?
|
| Diphosphates | 1 | 1977 | 88 | 0.010 |
Why?
|
| Cell Survival | 2 | 1980 | 5882 | 0.010 |
Why?
|
| Rabbits | 2 | 1975 | 4894 | 0.010 |
Why?
|
| Muscle Tonus | 1 | 1976 | 81 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1982 | 1504 | 0.010 |
Why?
|
| Muscle Proteins | 2 | 1974 | 1159 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2000 | 500 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1981 | 1189 | 0.010 |
Why?
|
| Bioprosthesis | 1 | 2000 | 596 | 0.010 |
Why?
|
| Skin | 1 | 1969 | 4364 | 0.010 |
Why?
|
| Cardiac Complexes, Premature | 2 | 1977 | 64 | 0.010 |
Why?
|
| Vagus Nerve | 2 | 1970 | 438 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 1686 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 11124 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1977 | 402 | 0.010 |
Why?
|
| Organization and Administration | 1 | 1975 | 52 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2005 | 1886 | 0.010 |
Why?
|
| Medical Records | 1 | 1980 | 1413 | 0.010 |
Why?
|
| Autopsy | 2 | 1984 | 1020 | 0.010 |
Why?
|
| Cardiovascular Abnormalities | 1 | 1955 | 144 | 0.010 |
Why?
|
| Cattle | 1 | 1981 | 3922 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 20822 | 0.010 |
Why?
|
| Central Nervous System | 2 | 1974 | 1357 | 0.010 |
Why?
|
| Venous Pressure | 1 | 1974 | 56 | 0.010 |
Why?
|
| Phenethylamines | 1 | 1974 | 96 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2002 | 1181 | 0.010 |
Why?
|
| Sinoatrial Node | 1 | 1974 | 101 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3297 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13102 | 0.010 |
Why?
|
| Cerebral Ventriculography | 1 | 1973 | 44 | 0.010 |
Why?
|
| Kinetics | 1 | 1981 | 6473 | 0.010 |
Why?
|
| Proteins | 2 | 1968 | 6103 | 0.010 |
Why?
|
| Patient Transfer | 2 | 1990 | 761 | 0.010 |
Why?
|
| Health Planning | 1 | 1975 | 238 | 0.010 |
Why?
|
| Lactates | 1 | 1974 | 432 | 0.010 |
Why?
|
| Vitamin D | 1 | 2007 | 3223 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1973 | 198 | 0.010 |
Why?
|
| Propantheline | 1 | 1972 | 6 | 0.010 |
Why?
|
| Chemoreceptor Cells | 2 | 1973 | 86 | 0.010 |
Why?
|
| Peer Review | 1 | 1975 | 209 | 0.010 |
Why?
|
| Academies and Institutes | 1 | 1975 | 317 | 0.010 |
Why?
|
| Myofibrils | 1 | 1973 | 146 | 0.010 |
Why?
|
| Quinidine | 1 | 1972 | 57 | 0.010 |
Why?
|
| Electromagnetic Phenomena | 1 | 1973 | 161 | 0.010 |
Why?
|
| Leg | 4 | 1971 | 1116 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1972 | 198 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 9386 | 0.010 |
Why?
|
| Aging | 2 | 1982 | 8664 | 0.010 |
Why?
|
| Myography | 1 | 1972 | 109 | 0.010 |
Why?
|
| Temperature | 2 | 1969 | 2206 | 0.010 |
Why?
|
| Manometry | 1 | 1974 | 445 | 0.010 |
Why?
|
| Ovulation | 1 | 1972 | 189 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1977 | 2187 | 0.010 |
Why?
|
| Heart-Lung Machine | 1 | 1971 | 43 | 0.010 |
Why?
|
| Bretylium Compounds | 1 | 1971 | 8 | 0.010 |
Why?
|
| Mesentery | 1 | 1972 | 205 | 0.010 |
Why?
|
| Digestive System | 1 | 1972 | 253 | 0.010 |
Why?
|
| Ilium | 1 | 1972 | 154 | 0.010 |
Why?
|
| Venae Cavae | 1 | 1970 | 41 | 0.010 |
Why?
|
| Mesenteric Veins | 1 | 1971 | 89 | 0.010 |
Why?
|
| Renal Veins | 1 | 1971 | 108 | 0.010 |
Why?
|
| Iliac Vein | 1 | 1971 | 72 | 0.010 |
Why?
|
| Technology, Radiologic | 1 | 1971 | 163 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 1972 | 197 | 0.010 |
Why?
|
| Blood Protein Disorders | 1 | 1970 | 8 | 0.010 |
Why?
|
| Menstruation | 1 | 1972 | 302 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1974 | 642 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1970 | 156 | 0.010 |
Why?
|
| Transducers | 1 | 1972 | 252 | 0.010 |
Why?
|
| Embryo Implantation | 1 | 1972 | 272 | 0.010 |
Why?
|
| Brachiocephalic Veins | 1 | 1970 | 23 | 0.010 |
Why?
|
| Feedback | 1 | 1974 | 795 | 0.010 |
Why?
|
| Phenols | 1 | 1974 | 497 | 0.010 |
Why?
|
| Neural Inhibition | 1 | 1974 | 602 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1974 | 934 | 0.010 |
Why?
|
| Sepsis | 1 | 1964 | 2593 | 0.010 |
Why?
|
| Electrodes | 1 | 1972 | 619 | 0.010 |
Why?
|
| Hindlimb | 1 | 1971 | 504 | 0.010 |
Why?
|
| Creatine | 1 | 1971 | 421 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1977 | 1809 | 0.010 |
Why?
|
| Chromium Isotopes | 1 | 1968 | 29 | 0.010 |
Why?
|
| Respiratory System | 1 | 1972 | 557 | 0.010 |
Why?
|
| Nervous System | 1 | 1972 | 554 | 0.010 |
Why?
|
| Iodine Isotopes | 1 | 1968 | 90 | 0.010 |
Why?
|
| Vena Cava, Superior | 1 | 1969 | 193 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1988 | 378 | 0.010 |
Why?
|
| Television | 1 | 1971 | 409 | 0.010 |
Why?
|
| Surface Tension | 1 | 1968 | 47 | 0.000 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1968 | 148 | 0.000 |
Why?
|
| Strontium | 1 | 1967 | 20 | 0.000 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 1970 | 209 | 0.000 |
Why?
|
| Uterus | 1 | 1972 | 711 | 0.000 |
Why?
|
| Infant, Newborn | 4 | 1968 | 25625 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1977 | 2107 | 0.000 |
Why?
|
| Boston | 1 | 1980 | 9313 | 0.000 |
Why?
|
| Hospitals | 1 | 2001 | 3952 | 0.000 |
Why?
|
| Phosphates | 1 | 1971 | 786 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1968 | 484 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1988 | 588 | 0.000 |
Why?
|
| Tourniquets | 1 | 1968 | 110 | 0.000 |
Why?
|
| Fluoroscopy | 1 | 1971 | 924 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 2 | 1968 | 1537 | 0.000 |
Why?
|
| Wound Healing | 1 | 1978 | 2785 | 0.000 |
Why?
|
| Rupture | 1 | 1968 | 433 | 0.000 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1970 | 314 | 0.000 |
Why?
|
| Fellowships and Scholarships | 1 | 1975 | 1076 | 0.000 |
Why?
|
| Cineradiography | 1 | 1965 | 24 | 0.000 |
Why?
|
| Skin Tests | 1 | 1968 | 613 | 0.000 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 1965 | 12 | 0.000 |
Why?
|
| Melena | 1 | 1965 | 34 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1968 | 546 | 0.000 |
Why?
|
| Hemorrhagic Disorders | 1 | 1965 | 36 | 0.000 |
Why?
|
| Thoracic Surgical Procedures | 2 | 1962 | 342 | 0.000 |
Why?
|
| Mandelic Acids | 1 | 1965 | 47 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1988 | 981 | 0.000 |
Why?
|
| Dipyridamole | 1 | 1985 | 145 | 0.000 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1986 | 234 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 35421 | 0.000 |
Why?
|
| Hypoxanthine | 1 | 1984 | 28 | 0.000 |
Why?
|
| Glucans | 2 | 1962 | 72 | 0.000 |
Why?
|
| Cardiography, Impedance | 1 | 1984 | 41 | 0.000 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1973 | 1004 | 0.000 |
Why?
|
| Pulmonary Veins | 1 | 1970 | 761 | 0.000 |
Why?
|
| Adenosine Triphosphatases | 1 | 1968 | 839 | 0.000 |
Why?
|
| Endocarditis, Bacterial | 1 | 1968 | 455 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1968 | 518 | 0.000 |
Why?
|
| Hemolysis | 1 | 1965 | 420 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1974 | 2972 | 0.000 |
Why?
|
| Serotonin | 1 | 1967 | 1017 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1968 | 1074 | 0.000 |
Why?
|
| Lung | 1 | 1981 | 9856 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1968 | 685 | 0.000 |
Why?
|
| Electric Stimulation Therapy | 1 | 1967 | 605 | 0.000 |
Why?
|
| Neurosurgery | 1 | 1967 | 643 | 0.000 |
Why?
|
| Chromatin | 1 | 1973 | 2934 | 0.000 |
Why?
|
| Hypothermia, Induced | 1 | 1966 | 752 | 0.000 |
Why?
|
| Endocrine Glands | 1 | 1960 | 103 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1968 | 4776 | 0.000 |
Why?
|
| Monitoring, Intraoperative | 1 | 1966 | 957 | 0.000 |
Why?
|
| Hypersensitivity | 1 | 1968 | 1102 | 0.000 |
Why?
|
| Homeostasis | 1 | 1970 | 3340 | 0.000 |
Why?
|
| Elapid Venoms | 1 | 1978 | 40 | 0.000 |
Why?
|
| Sarcolemma | 1 | 1978 | 66 | 0.000 |
Why?
|
| Erythrityl Tetranitrate | 1 | 1977 | 1 | 0.000 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1978 | 158 | 0.000 |
Why?
|
| Consciousness | 1 | 1983 | 572 | 0.000 |
Why?
|
| Tissue Preservation | 1 | 1978 | 182 | 0.000 |
Why?
|
| Respiratory Insufficiency | 1 | 1965 | 1199 | 0.000 |
Why?
|
| Punctures | 1 | 1957 | 374 | 0.000 |
Why?
|
| Sodium Chloride | 1 | 1977 | 625 | 0.000 |
Why?
|
| Microspheres | 1 | 1977 | 777 | 0.000 |
Why?
|
| Asthma | 1 | 1972 | 6011 | 0.000 |
Why?
|
| Carbon | 1 | 1977 | 687 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1976 | 1375 | 0.000 |
Why?
|
| Androsterone | 1 | 1970 | 14 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1978 | 2203 | 0.000 |
Why?
|
| Butyrates | 1 | 1970 | 163 | 0.000 |
Why?
|
| Diet Therapy | 1 | 1970 | 154 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1978 | 2969 | 0.000 |
Why?
|
| Intermittent Claudication | 1 | 1970 | 309 | 0.000 |
Why?
|
| Propylene Glycols | 1 | 1965 | 92 | 0.000 |
Why?
|